This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2022
ASCO GU 2022 Prostate Cancer
Conferences
ASCO GU 2022
Prostate Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Carcinoma
ASCO GU 2022 Prostate Cancer
Viewing 181-200 of 316 articles
ASCO GU 2022: Outcomes According to Histological Variants of Urothelial Carcinoma After Neoadjuvant Chemotherapy in the GETUG-AFU V05 VESPER Trial
ASCO GU 2022: Safety Lead-in of Phase II SBRT and Durvalumab with or Without Tremelimumab for Unresectable and Cisplatin-Ineligible, Locally Advanced or Metastatic Bladder Cancer
ASCO GU 2022: Tailored Immunotherapy Approach with Nivolumab in Advanced Transitional Cell Carcinoma (TITAN-TCC)
ASCO GU 2022: BAYOU: A Phase II, Randomized, Multicenter, Double-Blind, Study of Durvalumab in Combination With Olaparib for the First-Line Treatment of Platinum-Ineligible Patients With Unresectable, Stage IV Urothelial Carcinoma
ASCO GU 2022: A Randomized, Double Blind, Biomarker Selected, Phase II Clinical Trial of Maintenance PARP Inhibition Following Chemotherapy for Metastatic Urothelial Carcinoma: Final Analysis of the ATLANTIS Rucaparib Arm
ASCO GU 2022: NEXT: A Single-Arm, Phase 2, Open-Label Study of Adjuvant Nivolumab After Completion of Chemo-Radiation Therapy in Patients With Localized Muscle-Invasive Bladder Cancer
ASCO GU 2022: Vesical Imaging-Reporting and Data System (VI-RADS)
ASCO GU 2022: Genomic Characterization of Patients With De-Novo High-Volume Metastatic Castration-Sensitive Prostate Cancer Compared to Those Without
ASCO GU 2022: Quantifying Molecular Imaging Patterns of Treatment Response or Progression Using a Novel Traffic Light Workflow Within a Prospective Phase I/II Trial of 177LuPSMA-617 and NOX66 (LuPIN)
ASCO GU 2022: Survival Outcomes and Characterization of Patients With Metastatic Castration-Sensitive Prostate Cancer Undergoing Intensified ADT Who Do Not Achieve an Optimal PSA Response (PSA ≤0.2 Ng/ML)
ASCO GU 2022: Serial ctDNA Evaluation to Predict Clinical Progression in Patients with Advanced Urothelial Carcinoma
ASCO GU 2022: Clinical Implications of Molecular Biomarkers in Upper-Tract Urothelial Carcinoma
ASCO GU 2022: Implementation of PSMA-PET in Focal Dose-Escalated Radiotherapy of Primary Prostate Cancer Patients: Results of a Planned Safety Analysis of a Phase II Trial
ASCO GU 2022: Phase 2 Randomized Trial of ModraDoc006/R, Oral Docetaxel Plus Ritonavir, Versus Intravenous Docetaxel in Metastatic Castration Resistant Prostate Cancer
ASCO GU 2022: Tumor Mutational Burden as a Predictive Biomarker for Immune Checkpoint Inhibitor Versus Taxane Chemotherapy Benefit in Metastatic Castration-Resistant Prostate Cancer: A Real-World Biomarker Study
ASCO GU 2022: MiCheck Prostate Blood Test for Aggressive Prostate Cancer Designed for the Clinical Lab Setting
ASCO GU 2022: TROPHY-U-01 Cohort 3: Sacituzumab Govitecan in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cancer Who Progressed After Platinum-Based Regimens
ASCO GU 2022: Study EV-103 Cohort H: Antitumor Activity of Neoadjuvant Treatment with Enfortumab Vedotin Monotherapy in Patients with MIBC Who Are Cisplatin Ineligible
ASCO GU 2022: Comprehensive Molecular Characterization of MIBC Treated with Durvalumab plus Olaparib in the Neoadjuvant Setting: Neodurvarib Trial
ASCO GU 2022: Defining Hereditary Upper Tract Urothelial Carcinoma: Implications for Genetic Testing and Clinical Management
5
6
7
8
9
10
11
12
13
14
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free